SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
1.020
-0.030 (-2.86%)
At close: Apr 24, 2026, 4:00 PM EDT
1.030
+0.010 (0.98%)
After-hours: Apr 24, 2026, 7:12 PM EDT
SCYNEXIS Employees
SCYNEXIS had 18 employees as of December 31, 2025. The number of employees decreased by 10 or -35.71% compared to the previous year.
Employees
18
Change (1Y)
-10
Growth (1Y)
-35.71%
Revenue / Employee
$1,144,500
Profits / Employee
-$478,278
Market Cap
81.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 18 | -10 | -35.71% |
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2023 | 29 | -7 | -19.44% |
| Dec 31, 2022 | 36 | -20 | -35.71% |
| Dec 31, 2021 | 56 | 18 | 47.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| Alpha Teknova | 158 |
| Cumberland Pharmaceuticals | 93 |
| Journey Medical | 58 |
| Assertio Holdings | 53 |
| Cardiol Therapeutics | 18 |
| Incannex Healthcare | 12 |
SCYX News
- 24 days ago - Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Business Wire
- 24 days ago - SCYNEXIS Announces $40.0 Million Private Placement - GlobeNewsWire
- 24 days ago - SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - GlobeNewsWire
- 7 weeks ago - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - GlobeNewsWire
- 2 months ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 4 months ago - SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 5 months ago - SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - GlobeNewsWire